Premium
A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome
Author(s) -
Kurlan Roger,
Crespi Giovanna,
Coffey Barbara,
MuellerVahl Kirsten,
Koval Stephen,
Wunderlich Glen
Publication year - 2012
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.24919
Subject(s) - pramipexole , tourette syndrome , placebo , tics , clinical global impression , randomized controlled trial , psychology , medicine , attention deficit hyperactivity disorder , psychiatry , parkinson's disease , alternative medicine , disease , pathology
Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo‐controlled, double‐blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome. Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (−7.16) and placebo (−7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent‐ and investigator‐scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder. © 2012 Movement Disorder Society